A new study found that weight-loss medications like Ozempic and Mounjaro are not as effective in a “real-world” setting ...

WEDNESDAY, June 11, 2025 (HealthDay News) — Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and ...

The SURMOUNT-5 trial, a Phase 3b open-label clinical trial, examined the safety and efficacy of ... “In real-world terms, that means many patients on Zepbound are losing more weight than those ...

Researchers compared the safety and efficacy of tirzepatide (brand name Zepbound) and semaglutide (brand name Wegovy) in a 72-week clinical trial. The randomized, controlled trial — called ...

A new study published in the New England Journal of Medicine comparing Eli Lilly’s Zepbound to Novo Nordisk’s Wegovy — both approved to treat obesity — found that Zepbound is more ...

In an emailed statement to CBS News Monday, a spokesperson for Novo Nordisk, the maker of Wegovy and Ozempic, said both Wegovy and Zepbound have ... disease backed by real-world evidence." ...

In the real world, the use of semaglutide (Wegovy) and tirzepatide (Zepbound) produce far less ... which confirms the efficacy of this medications for the prevention of type 2 diabetes but also ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50 percent ... out in what Aronne said many view as “a drag race of efficacy,” both are important tools for treating obesity ...